Drawing for BISULFITOME

USPTO serial 79066457

BISULFITOME

Reviewed by CopyMark Law Group

Reg. 3828435Status 706Registered
Filing date
Status date
Registration date
Aug 3, 2010
Examiner
ROSSMAN, WILLIAM M
Law office
GENERIC WEB UPDATE

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with BISULFITOME?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Victoria Friedman

Victoria Friedman Dennemeyer & Associates, LLC2 North Riverside Plaza, Suite 1500Chicago, IL 60606UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemical, biochemical and biotechnological products for scientific and laboratory research purposes, namely, nucleic acids, enzymes and polymererases for laboratory and research use, [ diagnostic reagents and chemical buffers used for the isolation, purification or separation of nucleic acids, oligonucleotides or proteins, and protein arrays none of the foregoing for medical or veterinary purposes; ] chemical reagents [ and aromatic solvents ] for [ sample preparation, modification and manipulation of cells and for conducting marking, separating, isolating, purifying, ] amplification and/or analytic methods for natural and synthetic biopolymers, namely, nucleic acids, oligonucleotides, [ protein, ] macromolecules and biologically active substances in the nature of nucleic acids; kits comprised of chemical, biochemical and biotechnological products for [ sample preparation, purification, modification and manipulation of cells as well as for ] the performance of [ marking, separation, isolation, purification, ] amplification and analysis of biopolymers, namely, kits comprised of nucleic acids, enzymes, [ proteins, macromolecules and biologically active substances in the nature of nucleic acids from biological and biochemical sample material; ] all for scientific or laboratory research purposesACTIVE—
005[ Pharmaceutical and veterinary preparations for medical use including studies and research and development purposes, namely, nucleic acids sequences, chemical reagents and biochemical preparations; diagnostic preparations for medical purposes; diagnostic preparations for medical and veterinary purposes, namely, diagnostic preparations for sample preparation, modification and manipulation of samples and cells and diagnostic preparations for marking, separating, isolating, purifying, amplification and/or medical and veterinary analysis of biopolymers, in the nature of nucleic acids sequences, oligo-nucleotide arrays, probes, primers, aptamers, antisense-oligonucleotides, promoters, microRNA (miRNA), ribozymes; chemical, biochemical and biotechnological preparations for medical use, namely, medical and veterinary diagnostic reagents and solvents for medical and veterinary use for sample preparation, modification and manipulation of samples and cells and medical and for conducting marking, separating, isolating, purifying, amplifying and/or analysis of biopolymers, in the nature of nucleic acid sequences, protein arrays, macromolecules and biologically effective substances in the nature of nucleic acid sequences all for diagnostic medical purposes; in vitro diagnostics reagents for medical purposes; kits comprising diagnostic preparations for medical or veterinary diagnostic purposes, namely, for medical and veterinary sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, amplification and/or for the analysis of biopolymers, in the nature of nucleic acid sequences, oligo-nucleotide arrays, probes, primers, aptamers, antisense-oligonucleotides, promoters, microRNA (miRNA), ribozymes, proteins, macromolecules and biologically effective substances in the nature of nucleic acid sequences from biological and biochemical sample materials; all-purpose disinfectants ]SECTION 71 - CANCELLED—
009[ Scientific apparatuses, instruments and devices for the purpose of surveying, weighing, measuring, signaling and regulating apparatuses, instruments and devices for research, laboratory and scientific purposes, namely, disposable bottle liners for use with laboratory apparatus; disposable and re-useable dispenser syringes for laboratory use; scales, plastic sample storage, reaction and collection vessels, namely, plates and multi-well plates that can be used in chemical analysis, biological analysis or patterning for scientific, laboratory or medical research use; laboratory consumables, namely, pipette tips, filter tips and dispenser tips, pipette tips and carrying pipette tip boxes; laboratory storage tubes, namely, test tubes, micro tubes and tubes for Polymerase Chain Reaction (PCR); micro-laboratory centrifuges and laboratory micro-injectors; laboratory equipment namely, cuvettes, spin columns, chromatography columns and cartridges filled with chromatographic materials for the purpose of separation, purification and isolation of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances in the nature of nucleic acids from biological and biochemical sample materials for scientific or laboratory use; racks and holders for sample laboratory storage tubes and beakers, tubes, syringes and pipette tips; scientific instrument used in laboratory sample preparation, namely, magnetic beads for magnetic particle separation and handling and analyzing nucleic acids, proteins, enzymes, and chemicals; laboratory filters, namely, filter membranes for biotechnological and scientific purposes, namely, filter membranes and filter devices comprised of laboratory spin columns, tubes, plates, silica materials and filter strips in a microtitration format for the isolation and purification of nucleic acids and oligonucleotides, and other biological materials for laboratory and scientific use; sample presentation devices, namely, laboratory research micro-arrays, silicon chips, and Matrix-Assisted Laser Desorption/Ionization (MALDI) presentation device, namely, laser desorption plates for analyzing, diagnosing and presenting data in the field of spectrometry all used for laboratory or medical research; laboratory robots and robotic workstations comprising computer hardware for laboratory robots; laboratory incubators for diagnostic, clinical and research applications for the preparation, modification, isolation, crystallization, handling, amplification and manipulation of samples and for the marking, separation, isolation, purification, reproduction and analysis of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material; laboratory apparatus and equipment, namely, computer hardware and software for dosage, dispensing, transferring, temperature equalizing, agitating, mixing, diluting, concentrating and separating of liquids; laboratory apparatus, namely, MALDI laser desorption plates for use in analytical analysis, medical, diagnostic and research workstations comprised of computer hardware and software for reading and handling multi-well plates for the analysis of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample materials; laboratory equipment, namely, thermal cyclers and cell disrupters; physico-chemical, biochemical, optical and electronic analysis apparatuses and equipment, namely, photometers, spectrophotometers, optical scanners for detection of fluorescence and colorimetric signals; apparatuses and instruments for processing cells or liquids containing cells namely, electroporators, micro-injectors and micro-manipulators; scientific apparatus, namely, ultra high vacuum chambers for chromatography, purification, separation and characterization of natural and synthetic biopolymers, nucleic acids, oligo-nucleotides, proteins, macromolecules and biologically active substances from sample materials; centrifuges for laboratory use; vacuum manifold and one or more membrane holders for filtration of liquids for laboratory use; scientific apparatus for laboratory use, namely, centrifugal vacuum concentrators designed to separate, concentrate, centrifuge and dry biological and chemical materials; rotors for laboratory centrifuges and vacuum concentrators and microtube mixers for laboratory use; mechanical, electronic and automatic pipettes and dispensers for dispensing liquid for laboratory research and analysis purposes ]SECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 16, 2021INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Aug 2, 2021INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Dec 2, 2020NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Dec 2, 202071AGREGISTERED-SEC.71 ACCEPTED—
Nov 25, 2020APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jul 31, 2020ES71TEAS SECTION 71 RECEIVED—
Aug 3, 2019REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Nov 22, 2018RNWLINTERNATIONAL REGISTRATION RENEWED—
Oct 18, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jun 23, 2017INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
May 4, 2017INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
May 4, 2017INPCINVALIDATION PROCESSED—
Apr 29, 2017INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 29, 2016NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Aug 29, 2016C75PREGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.—
Aug 25, 2016APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jul 19, 2016ES75TEAS SECTION 71 & 15 RECEIVED—
Aug 22, 2014NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 12, 2013NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 12, 2013FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Nov 5, 2010FICSFINAL DISPOSITION NOTICE SENT TO IB—
Nov 5, 2010FIMPFINAL DISPOSITION PROCESSED—
Nov 3, 2010FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 3, 2010R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 18, 2010NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 18, 2010PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 12, 2010PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Apr 12, 2010CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 10, 2010XAECEXAMINER'S AMENDMENT ENTERED—
Apr 10, 2010GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Apr 10, 2010GNEAEXAMINERS AMENDMENT E-MAILED—
Apr 10, 2010CNEAEXAMINERS AMENDMENT -WRITTEN—
Apr 6, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 5, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 5, 2010ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Mar 5, 2010GNS1NOTIFICATION OF SUBSEQUENT FINAL EMAILED—
Mar 5, 2010GNCFCONTINUATION OF FINAL REFUSAL E-MAILED—
Mar 5, 2010CNCFACTION CONTINUING A FINAL - COMPLETED—
Feb 17, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 17, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 17, 2010ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Aug 27, 2009GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Aug 27, 2009GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 27, 2009CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 3, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 3, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 3, 2009ALIEASSIGNED TO LIE—
Jul 16, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 14, 2009ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 14, 2009REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 15, 2009RFNTREFUSAL PROCESSED BY IB—
Apr 21, 2009RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 21, 2009RFRRREFUSAL PROCESSED BY MPU—
Apr 19, 2009RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 18, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 14, 2009MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 10, 2009DOCKASSIGNED TO EXAMINER—
Apr 10, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 9, 2009REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance